Report Description Table of Contents Industry Report and Statistics (Facts & Figures) - Demand & Sales by Product Type & Application The global soft tissue allografts market will witness a robust CAGR of 4.72%, valued at $12.93 billion in 2021, expected to appreciate and reach $19.58 billion by 2030, confirms Strategic Market Research. North America led the industry with a total share of around 43.51 % in 2021. Soft tissues support and connect other tissues and surround the organs in the body. They inculcate muscles (including the heart), blood vessels, fat, tendons, nerves and tissues surrounding the joints and bones. The most common musculoskeletal soft tissue injury occurs in muscles, tendons, and ligaments. According to the recent analysis of the Global Burden of Disease (GBD), approximately 1.71 billion people globally have musculoskeletal conditions that include lower back pain as the main contributor (28%), fractures (21%), osteoarthritis (17%), neck pain (11%), amputations (8%) and rheumatoid arthritis (1%). Types of Soft-tissue injuries: Injuries in the Soft- Tissues are classified as follows: Contusions (bruises): A blunt impact, such as a kick, tumble, or a hit that causes pain, edema, and discolouration in the tissue, resulting in discomfort, swelling, and discolouration. Sprains: It's a partial ligament tear usually induced by a twist or a wrench. Sprains can happen due to sudden twisting, turning, or rolling motions. Tendonitis: It's usually caused by repetitive motion in the affected location, which can affect the elbow, hand, wrist, shoulder, hip, knee, ankle, and foot. Bursitis: The bursa, a fluid-filled sac that acts as a cushion between bones and muscles or tendons, is inflamed. Stress injuries: It's a small crack in a bone that most usually affects the lower extremities' weight-bearing bones, such as the legs, hips, and feet. Strain: It is a muscle or tendon injury frequently caused by overuse, force, or stretching. Procedure: An allograft is a tissue transplanted from one person to another. It is harvested from a human donor within the time span of 12-24 hours post death. Harvest of these tissues is conducted and performed by surgeons or specially trained technicians with ethanol, followed by gamma irradiation for bacterial, fungal, and viral sterilization. Allografts are then processed, tested , packaged, and distributed by the tissue banks. As per the findings of the American Association of Tissue Banks, the demand for musculoskeletal grafts has grown manifolds. Each year, over 2.5 million life-saving and healing tissue transplants are performed, providing patients with a new shot at a healthy, productive, and normal life. The AATB provides accreditation for over 127 tissue banks worldwide. Types of Allograft: Musculoskeletal system includes your bones, cartilage, ligaments, tendons, and connective tissues. Musculoskeletal allografts are of the following types: Meniscus Allograft: The meniscus (c-shaped cartilage in the knee) is replaced. Cartilage (Osteochondral) Allograft: A piece of tissue containing bone and cartilage is replaced that lines the ends of bones in a joint. Tendon (Collagen) Allograft: Replaces torn or frayed tendon due to overuse or injury. Dental Allograft: It adds volume and density to jaws in areas where bone loss has occurred. Nerve Allograft: Peripheral nerve discontinuities can be surgically repaired. Market Drivers - Rising Old age Population, Increase in Sports Related Injuries and High Success Rates Rising Old age Population: Older people are more likely to suffer from various soft tissue injuries. It's natural to slow down, have less energy, and not be so powerful as we get older. We are also more vulnerable to get harmed as a result of these circumstances. Falls are the biggest cause of death in those over 65, with falls being the most prevalent reason for them to attend the emergency room. Increase in sports injuries: An accident, impact, bad training habits, lack of conditioning, incorrect equipment, insufficient warm-up & stretching can result in a sports injury. Youth injuries are on the rise due to year-round participation in a single sport. As per the findings of the American Academy of Pediatrics, In the United States, about 30 million children & teenagers participate in organized sports, resulting in more than 3.5 million injuries each year. Sports-related injuries make up to a third of all injuries in children. High Success rate: Allografts have witnessed substantial clinical success in many soft tissue reconstructive processes, including anterior cruciate ligament (ACL) reconstruction, one of today's most prevalent orthopaedic procedures. Owing to the high success rate and growing awareness, the demand for musculoskeletal allografts is on the rise. As per the latest findings of the American Academy of Orthopedic Surgeons, more than 5 million musculoskeletal allografts have been allowed and allocated to surgeons in the past decade. Restraints - High Cost and Morbidity High Cost: The costs of unintentional injuries are huge. The burden on employers and society runs in billions of dollars annually. According to National Safety Council, the total economic cost of nonfatal and fatal preventable injury-related incidents in 2020 was $1,158.4 billion, which included costs due to Motor vehicle crashes (39%), Home Injuries (33%), work injury (14%), and Public injuries (14%). Furthermore, the medical cost of all these injuries accounted for 20.4% of the economic cost. Morbidity: Tissue allografts can substantially improve the quality of life for many patients. However, infections associated with bacterial contamination of allografts can result in serious morbidity and death. According to the CDC's (Centers for Disease Control and Prevention) National Nosocomial Infection Surveillance System, postoperative orthopaedic infection rates range from 0.6% to 2%. Opportunities Less Healing Time: Biological grafts take less time to heal and have fewer issues of rejection. Both bone and soft tissue healing undergo a natural response involving fibrovascular tissue formation and eventual bony incorporation at the healing interface. As per the journal published in The American Journal of Sports Medicine, Several soft tissue models have witnessed sufficient tendon-to-bone healing (using the semitendinosus tendon in an animal model) within the time frame of 3 to 24 weeks. Rising Sports Injuries: There is an immediate need to control blood loss and achieve effective hemostasis and wound closure in injuries, trauma or surgical procedures. According to injury statistics from Consumer Product Safety Commission, 2.7 million Sports and recreational injuries were estimated in 2020. Sports that entail contact and collisions, such as racing, exercising, basketball, football, and soccer, have the highest injury rates. Market Analysis Of Different Segments Covered in the Report Based on Product Type Cartilage Tendon Allograft Meniscus Allograft Dental Allograft Collagen Allograft Amniotic Allograft Based on Application Orthopedic Dentistry Wounded care Others Based on End User Hospitals Orthopedic Clinics Dental Clinics Ambulatory Service Centers Aesthetic Centers Regional Coverage Analysis North America US Canada Rest of North America Europe United Kingdom Germany Italy France Russia Spain Rest of Europe Asia-Pacific China Japan Australia India Singapore South Korea Rest of Asia-Pacific LAMEA Argentina Brazil Saudi Arabia South Africa United Arab Emirates Rest of LAMEA Segments Analysis & Insights By Type, the Collagen allograft segment spearheaded the soft tissue allografts market because vascular and orthopedic surgeons mostly utilize these devices to treat diabetic foot ulcers, perform ACL surgeries, and conduct other cosmetic surgeries. By Application, the Orthopaedic segment held the largest industry share due to the continuously expanding geriatric population, increasing life expectancy, improving consumer attitude towards minimally invasive healthcare procedures, and growing bone disorders worldwide. However, the Dental segment is poised to show the fastest growth rate due to the growing number of patients undergoing dental treatments. Furthermore, rising oral cancer, tooth decay, and an ageing population, all contribute to the growth of the soft tissue allograft market. By End User, the Hospital segment captures the highest share in the industry due to the rapid increase in surgeries across the world, the increasing elderly population, and the rising prevalence of various diseases. According to the injury facts by National Safety Council (2020), In the US, Nearly twice as many males (3.44 Million) were injured as females (1.83 Million), and 91% of all 5.27 Million injuries victims were treated in hospital emergency departments and released. By Region, North America leads the soft tissue allografts market share, followed subsequently by Europe due to the prevailing and much high tech healthcare system and higher adoption rate of much advanced products and technologies. As far as the soft tissue allografts fastest growing industry is concerned, the Asia Pacific region is the frontrunner. The region is driven by key players setting up distribution channels and the increased demand for collagen allografts to treat severe burn injuries and breast reconstruction operations. As per the findings of The American Association of Tissue Banks (AATB), 3.3 million allografts are distributed by 58000 tissue donors. 2,800 Specialists have been awarded the Certified Tissue Banking Specialist (CTBS) certifications till date. Most of the human tissues distributed for transplant comes from AATB accredited tissue banks. Soft Tissue Allografts Market Report Coverage Report Attribute Details Forecast Period 2021 - 2030 Market size value in 2021 USD 12.93 Billion Revenue forecast in 2030 USD 19.58 Billion Growth rate CAGR of 4.72% The base year for estimation 2021 Historical data 2017 – 2020 Unit USD Billion, CAGR (2021 - 2030) Segmentation Type, Application, End-User, and Region By Type Meniscus Allograft, Cartilage (Osteochondral) Allograft, Tendon (Collagen) Allograft, Dental Allograft, Others By Application Dentistry, Orthopedic, Wound Care and Others By End-User Hospitals, Aesthetic Centres, Orthopedic Clinics, Dental Clinics and Other End Users By Region North America, Asia-Pacific, Europe, Latin America the Middle-East and Africa. Country Scope US, Mexico, Canada, Germany, UK, France, China, Japan, India etc. Company Usability Profiles Mimedix Group,Zimmer Biomet,Lattice Biologics Ltd, AlonSource, Conmed Corporation, AlloSource, Osiris Therapeutics, Globus Medical,Inc., Organogenesis, Inc. , RTI Surgical, Inc., Arthrex, Xtant Medical , Alliqua Biomedical, Inc., Integra Life sciences Corporation. Global Soft Tissue Allografts Market Competitive Landscape Analysis The report outlines the most pertinent competitors operating in a global industry. The comparison is performed based on overall revenue generation, investments by the venture capitalists, market initiatives, company overview, production analysis,R&D Investment,value chain optimization, market share financials,SWOT Analysis,company strengths and weaknesses, production capacity, global presence, production sites and facilities, and market potential, and many other variables. MiMedix Group Zimmer Biomet Lattice Biologics Ltd. Alon Source Conmed Coporation AlloSource Osiris Therapeutics Globus Medical, Inc. Organogenesis, Inc. Integra Life Sciences Corporation RTI Surgical, Inc. Straumann Holding AG Arthrex Alliqua BioMedical, Inc. Bard, Inc. (Davol, Inc.)Braun Melsungen AG Xtant Medical Recent Developments Worldwide: In August 2021, CYGNUS Matrix Disks, the latest form of amniotic tissue allografts, was launched by Vivex Biologics, a company specializing in developing naturally sourced medicines. The amniotic membrane is a semi-transparent, pliable membrane that lines the placenta's top cavity. During fetal development, amniotic tissue serves as an immune-privileged protective barrier. CYGNUS is used as a soft tissue barrier and wound dressing to give mechanical protection while retaining endogenous growth factors. CYGNUS amniotic tissue allografts are used as a soft tissue barrier and wound covering for mechanical support. CYGNUS Matrix Disks are a multi-layer allograft that keeps the amnion, intermediate/spongy, and chorion layers of the amniotic sac intact, allowing for easier handling and workability. In August 2021, To support demanding soft tissue applications, AlloSource launched the AlloMend Ultra-Thick Acellular Dermal Matrix, the thickest in the AlloMend product line. AlloMend Ultra-Thick ADM is available in a range of thicknesses from 3.0 to 4.0mm and is made by utilizing cutting-edge processing procedures to ensure that the thickness of each allograft is uniform throughout the graft. AlloSource created the substance for use in treatments that need the repair or replacement of injured or inadequate tissue, such as superior capsule reconstruction (SCR). Sutures with good suture retention and ultimate tensile strength are required for these procedures. AlloSource is a non-profit organization that helps surgeons heal their patients by delivering allografts that maximize tissue donation. The organization has developed into one of the country's largest tissue networks, producing over 200 precision bone, skin, soft-tissue, and custom-machined allografts for various life-saving and life-enhancing medical treatments. In March 2021, Sparta Biopharma, Inc., a privately held company focused on developing osteobiologics for sports medicine, announced the commercial availability of BioEnthesis, the first-of-its-kind allograft with both demineralized and mineralized layers that provide the necessary properties for rotator cuff repair and healing. BioEnthesis is a biphasic cancellous bone allograft with the structural and handling features of a soft tissue allograft, including a complete porous collagenous matrix for the purpose of soft tissue ingrowth and a calcified layer for assisting osseointegration. It acts as a scaffold to help mend the enthesis's bone while providing a solid basis for tendon integration. According to the Healthcare Cost and Utilization Project, rotator cuff pain and dysfunction account for more than 4.5 million physician visits. In January 2021, Direct Biologics, LLC, a leader in extracellular vesicle technology, announced the clinical availability of AmnioWrap placental based sheet allografts. AmnioWrap is a one-of-a-kind triple layer graft for chronic and acute wounds. The allograft comprises an extracellular collagen matrix and a variety of regulatory proteins such as growth factors, cytokines, and chemokines, all of which are known to have a role in tissue repair and regeneration. AmnioWrap is a dehydrated and sterilized human amniotic/chorionic membrane allograft designed for homologous usage in human tissue repair, replacement, reconstruction, and augmentation. It has an intact extracellular matrix (ECM), regulating growth factors and cytokines found in human placental tissues. AmnioWrap is a topically applied material that has been utilized for surgical applications, wounds, burns, soft tissue injuries, and over tendons and ligaments. Various Advanced Devices and Equipments that Key Market Leaders Develop: Product Function Key players CopiOs Used as Buccal tissue matrix Zimmer Biomet VersaShield Used as Orthopedic tissue membrane Orthofix Cortiva Used as Orthopedic tissue matrix RTI Surgical CryoPatch Used as Cardiac tissue matrix Cryolife Frequently Asked Question About This Report What is the total market worth of soft tissue allografts market? The Soft tissue allografts market was valued at USD 12.93 billion in 2021. What are the key industry trends of the global soft tissue allografts market? The global soft tissue allografts market forecast suggests growth of USD 19.58 Bn by 2030 with a CAGR of 4.72%. How big is the soft tissue allografts market? The global soft tissue allografts market size was $12.93 Bn in 2021 and is predicted to reach $19.58 Bn by 2030, with a CAGR of 4.72%. What is the estimated value of the Global Soft Tissue Allografts Market? By 2030, the global soft tissue allografts market will reach USD 19.58 billion. What is the growth rate of the Global Soft Tissue Allografts Market? The market is poised to grow with a healthy CAGR of 4.72%. What is the projected CAGR of the soft tissue allografts market in the forecasted period? In the forecasted period 2021-2030 Global Soft Tissue Allografts Market is poised to grow with a CAGR of 4.72%. North America is expected to remain the soft tissue allografts largest market. Briefly describe the procedure and some applications in soft tissue allograft? The procedure begins with sterilizing human tissue allograft that is achieved safely and effectively by gamma irradiation. Then with arthroscopy and using a soft tissue marker, One can obtain high-precision placement under image guidance. Soft tissue allograft transplantation finds its Application in the field of knee reconstruction, anterior cruciate ligament reconstruction, Plastic Surgery, Vascular Surgery, Colorectal Surgery, Cardiothoracic Surgery, allograft Bone Transplant, Andrology and In Vitro Fertilization, Urology, Spine/Neurology, Dentistry and other Sports medicine applications via arthroscopy. Hence the allograft tissue companies are focusing on Tissue engineering. What is the soft tissue allografts market growth? The global soft tissue allografts market is expected to grow at a compound annual growth rate (CAGR) of 4.72% from 2021 to 2030 to reach USD 19.58 billion by 2030. Sources https://www.cdc.gov/nhsn/pdfs/pscmanual/9pscssicurrent.pdf https://www.who.int/news-room/fact-sheets/detail/musculoskeletal-conditions https://injuryfacts.nsc.org/all-injuries/costs/societal-costs/data-details 1. Introduction 1.1. Study Objective 1.2. Market Definition 1.3. Study Scope 1.3.1. Markets Covered 1.3.2. Geographic Scope 1.3.3. Years Considered 1.3.4. Stakeholders 2. Research Methodology 2.1. Data Procurement 2.2. Paid Database 2.2.1. Secondary Data 2.2.1.1. Key Secondary sources 2.2.2. Primary Data 2.2.2.1 Primary sources 2.2.2.2. Key industry insights 2.2.2.3. Primary interviews with experts 2.2.2.4. Key primary respondent list 2.3. Market Size Estimation 2.4. Bottom-Up and Top-Down Approaches 2.4.1. Bottom-Up Approach 2.4.1.1. Approach for arriving at Market size by bottom-up analysis 2.4.2. Top-Down Approach 2.4.2.1. Approach for Capturing Market Size by Top-Down Analysis 2.5. Market Breakdown and Data Triangulation 2.6. Research Methodology 2.7. Risk Assessment 3. Executive Summary 3.1 Soft Tissue Allografts Market: Post-Covid-19 3.1.1 Actual Scenario 3.1.2 Pessimistic Scenario 3.1.3 Optimistic Scenario 3.1.4 Market Summary 4. Industry Outlook 4.1 Market Snapshot 4.2 Soft Tissue Allografts Market 4.2.1 Market, 2021 – 2030 (USD Million) 4.3 Regional Business Analysis 4.3.1 Market, by region, 2021-2030 (USD Million) 4.4 By Product Business Analysis 4.4.1 Market, By Product, 2021-2030 (USD Million) 4.5 By End-User Business Analysis 4.5.1 Market, By End-User, 2021-2030 (USD Million) 4.6 Application Business Analysis 4.6.1 Market, By Application, 2021-2030 (USD Million) 4.7 Value Chain Analysis 4.8 Market Variable Analysis 4.8.1 Market Drivers Analysis 4.8.2 Market Restraints Analysis 4.9Business Environment Analysis Tool 4.9.1 Market PEST analysis 4.9.2 Market Porter’s analysis 4.10Penetration & Growth Prospect Mapping 5. Market Dynamics 5.1. Introduction 5.2. Market Dynamics 5.2.1. Drivers 5.2.2. Restraints 5.2.3. Opportunities 5.2.4. Challenges 5.3. Impact of Covid-19 On Market 5.4. Value Chain Analysis 5.5. Ecosystem 5.6. Patent Analysis 5.7. Trade Analysis 5.8. Tariff Analysis 5.9. Case Study Analysis 5.10. Porter’s Five Forces Analysis 5.10.1 Threat of New Entrants 5.10.2 Threat of Substitutes 5.10.3 Bargaining Power of Buyers 5.10.4 Bargaining Power of Suppliers 5.10.5 Degree of Competition 5.11. Application Analysis 5.11.1. Trends in Application (2014-2020) 5.11.2. Trends in Application (2021-2028) 5.12. Pricing Analysis 5.12.1. Average Price Trend Analysis (By Region, By Countries) 6. Competitive & Vendor Landscape 6.1. Company Market Share Analysis 6.2. Manufacturers Manufacturing Sites, Area Served, Product 6.3. Market Competitive Situation and Trends 6.4. Manufacturers Mergers & Acquisitions, Expansion Plans 7. Market: By Product Segment Analysis 7.1. Introduction 7.2. Sales Volume & Revenue Analysis (2021-2030) 7.3. Cartilage 7.3.1. Cartilage, 2021-2030 (USD Million) 7.4. Tendon Allograft 7.4.1. Tendon Allograft Market, 2021-2030 (USD Million) 7.5. Meniscus Allograft 7.5.1. Meniscus Allograft Market, 2021-2030 (USD Million) 7.6. Dental Allograft 7.6.1. Dental Allograft Market, 2021-2030 (USD Million) 7.7. Collagen Allograft 7.7.1. Collagen Allograft Market, 2021-2030 (USD Million) 7.8. Amniotic Allograft 7.8.1. Amniotic Allograft Market, 2021-2030 (USD Million) 8. Market: By End-User Segment Analysis 8.1. Introduction 8.2. Sales Volume & Revenue Analysis (2021-2030) 8.3. Hospitals 8.3.1. Hospitals Market, 2021-2030 (USD Million) 8.4. Orthopedic Clinics 8.4.1. Orthopedic Clinics Market, 2021-2030 (USD Million) 8.5. Dental Clinics 8.5.1. Dental Clinics Market, 2021-2030 (USD Million) 8.6. Ambulatory Service Centers 8.6.1. Ambulatory Service Centers Market, 2021-2030 (USD Million) 8.7. Aesthetic Centers 8.7.1. Aesthetic Centers Market, 2021-2030 (USD Million) 9. Market: By Application Segment Analysis 9.1. Introduction 9.2. Sales Volume & Revenue Analysis (2021-2030) 9.3. Orthopedic 9.3.1. Orthopedic Market, 2021-2030 (USD Million) 9.4. Dentistry 9.4.1. Dentistry Market, 2021-2030 (USD Million) 9.5. Wounded care 9.5.1. Wounded care Market, 2021-2030 (USD Million) 9.6. Others 9.6.1. Others Market, 2021-2030 (USD Million) 10. Market: Regional Outlook 10.1 North America 10.1.1. North America Market, By Product, 2021-2030 (USD Million) 10.1.2. North America Market, By End-User, 2021-2030 (USD Million) 10.1.3. North America Market, by Application, 2021-2030 (USD Million) 10.1.4. North America Market, by Country, 2021-2030 (USD Million) 10.1.4.1. U.S. 10.1.4.1.1. U.S. Market, By Product, 2021-2030 (USD Million) 10.1.4.1.2. U.S. Market, By End-User, 2021-2030 (USD Million) 10.1.4.1.3. U.S. Market, by Application, 2021-2030 (USD Million) 10.1.4.2. Canada 10.1.4.2.1. Canada Market, By Product, 2021-2030 (USD Million) 10.1.4.2.2. Canada Market, By End-User, 2021-2030 (USD Million) 10.1.4.2.3. Canada Market, by Application, 2021-2030 (USD Million) 10.2. Europe 10.2.1. Europe Market, By Product, 2021-2030 (USD Million) 10.2.2. Europe Market, By End-User, 2021-2030 (USD Million) 10.2.3. Europe Market, by Application, 2021-2030 (USD Million) 10.2.4. Europe Market, by country, 2021-2030 (USD Million) 10.2.4.1 U.K. 10.2.4.1.1. U.K. Market, By Product, 2021-2030 (USD Million) 10.2.4.1.2. U.K. Market, By End-User, 2021-2030 (USD Million) 10.2.4.1.3. U.K. Market, by Application, 2021-2030 (USD Million) 10.2.4.2. Germany 10.2.4.2.1. Germany Market, By Product, 2021-2030 (USD Million) 10.2.4.2.2. Germany Market, By End-User, 2021-2030 (USD Million) 10.2.4.2.3. Germany Market, by Application, 2021-2030 (USD Million) 10.2.4.3. France 10.2.4.3.1. France Market, By Product, 2021-2030 (USD Million) 10.2.4.3.2. France Market, By End-User, 2021-2030 (USD Million) 10.2.4.3.3. France Market, by Application, 2021-2030 (USD Million) 10.2.4.4. Rest of Europe 10.2.4.4.1. Rest of Europe Market, By Product, 2021-2030 (USD Million) 10.2.4.4.2. Rest of Europe Market, By End-User, 2021-2030 (USD Million) 10.2.4.4.3. Rest of Europe Market, by Application, 2021-2030 (USD Million) 10.3. Asia Pacific 10.3.1. Asia Pacific Market, By Product, 2021-2030 (USD Million) 10.3.2. Asia Pacific Market, By End-User, 2021-2030 (USD Million) 10.3.3. Asia Pacific Market, by Application, 2021-2030 (USD Million) 10.3.4. Asia Pacific Market, by country, 2021-2030 (USD Million) 10.3.4.1. China 10.3.4.1.1. China Market, By Product, 2021-2030 (USD Million) 10.3.4.1.2. China Market, By End-User, 2021-2030 (USD Million) 10.3.4.1.3. China Market, by Application, 2021-2030 (USD Million) 10.3.4.2. India 10.3.4.2.1. India Market, By Product, 2021-2030 (USD Million) 10.3.4.2.2. India Market, By End-User, 2021-2030 (USD Million) 10.3.4.2.3. India Market, by Application, 2021-2030 (USD Million) 10.3.4.3. Japan 10.3.4.3.1. Japan Market, By Product, 2021-2030 (USD Million) 10.3.4.3.2. Japan Market, By End-User, 2021-2030 (USD Million) 10.3.4.3.3. Japan Market, by Application, 2021-2030 (USD Million) 10.3.4.4. South Korea 10.3.4.4.1. South Korea Market, By Product, 2021-2030 (USD Million) 10.3.4.4.2. South Korea Market, By End-User, 2021-2030 (USD Million) 10.3.4.4.3. South Korea Market, by Application, 2021-2030 (USD Million) 10.3.4.5. Rest of ASIA PACIFIC 10.3.4.5.1. Rest of ASIA PACIFIC Market, By Product, 2021-2030 (USD Million) 10.3.4.5.2. Rest of ASIA PACIFIC Market, By End-User, 2021-2030 (USD Million) 10.3.4.5.3. Rest of ASIA PACIFIC Market, by Application, 2021-2030 (USD Million) 10.4. Latin America 10.4.1. Latin America Market, By Product, 2021-2030 (USD Million) 10.4.2. Latin America Market, By End-User, 2021-2030 (USD Million) 10.4.3. Latin America Market, by Application, 2021-2030 (USD Million) 10.4.4. Latin America Market, by country, 2021-2030 (USD Million) 10.4.4.1. Brazil 10.4.4.1.1. Brazil Market, By Product, 2021-2030 (USD Million) 10.4.4.1.2. Brazil Market, By End-User, 2021-2030 (USD Million) 10.4.4.1.3. Brazil Market, by Application, 2021-2030 (USD Million) 10.4.4.2. Mexico 10.4.4.2.1. Mexico Market, By Product, 2021-2030 (USD Million) 10.4.4.2.2. Mexico Market, By End-User, 2021-2030 (USD Million) 10.4.4.2.3. Mexico Market, by Application, 2021-2030 (USD Million) 10.4.4.3. Rest of Latin America 10.4.4.3.1. Rest of the Latin America Market, By Product, 2021-2030 (USD Million) 10.4.4.3.2. Rest of the Latin America Market, By End-User, 2021-2030 (USD Million) 10.4.4.3.3. Rest of the Latin America Market, by Application, 2021-2030 (USD Million) 10.5. MEA 10.5.1. MEA Market, By Product, 2021-2030 (USD Million) 10.5.2. MEA Market, By End-User, 2021-2030 (USD Million) 10.5.3. MEA Market, by Application, 2021-2030 (USD Million) 10.5.4. MEA Market, by Region, 2021-2030 (USD Million) 11. Competitive Landscape 11.1 MiMedix Group. 11.1.1. Company overview 11.1.2. Financial performance 11.1.3. ProductPortfolio Analysis 11.1.4. Business Strategy & Recent Development 11.2. Zimmer Biomet 11.2.1. Company overview 11.2.2. Financial performance 11.2.3. Product Portfolio Analysis 11.2.4. Business Strategy & Recent Development 11.3. Lattice Biologics Ltd 11.3.1. Company overview 11.3.2. Financial performance 11.3.3. Product Portfolio Analysis 11.3.4. Business Strategy & Recent Development 11.4. Alon Source 11.4.1. Company overview 11.4.2. Financial performance 11.4.3. Product Portfolio Analysis 11.4.4. Business Strategy & Recent Development 11.5. Conmed Coporation 11.5.1. Company overview 11.5.2. Financial performance 11.5.3. Product Portfolio Analysis 11.5.4. Business Strategy & Recent Development 11.6. AlloSource 11.6.1. Company overview 11.6.2. Financial performance 11.6.3. Product Portfolio Analysis 11.6.4. Business Strategy & Recent Development 11.7. Osiris Therapeutics 11.7.1. Company overview 11.7.2. Financial performance 11.7.3. Product Portfolio Analysis 11.7.4. Business Strategy & Recent Development 11.8. Welch Ally 11.8.1. Company overview 11.8.2. Financial performance 11.8.3. Product Portfolio Analysis 11.8.4. Business Strategy & Recent Development 11.9. Globus Medical, Inc. 11.9.1. Company overview 11.9.2. Financial performance 11.9.3. Product Portfolio Analysis 11.9.4. Business Strategy & Recent Development 11.10. Organogenesis, Inc 11.10.1. Company overview 11.10.2. Financial performance 11.10.3. Product Portfolio Analysis 11.10.4. Business Strategy & Recent Development 11.11. Integra Life Sciences Corporation 11.11.1. Company overview 11.11.2. Financial performance 11.11.3. Product Portfolio Analysis 11.11.4. Business Strategy & Recent Development 11.12. RTI Surgical, Inc 11.12.1. Company overview 11.12.2. Financial performance 11.12.3. Product Portfolio Analysis 11.12.4. Business Strategy & Recent Development 11.13. Straumann Holding AG 11.13.1. Company overview 11.13.2. Financial performance 11.13.3. Product Portfolio Analysis 11.13.4. Business Strategy & Recent Development 11.14. Arthrex 11.14.1. Company overview 11.14.2. Financial performance 11.14.3. Product Portfolio Analysis 11.14.4. Business Strategy & Recent Development 11.15. Alliqua BioMedical, Inc 11.15.1. Company overview 11.15.2. Financial performance 11.15.3. Product Portfolio Analysis 11.15.4. Business Strategy & Recent Development 11.16. Bard, Inc. (Davol, Inc.) Braun Melsungen AG 11.16.1. Company overview 11.16.2. Financial performance 11.16.3. Product Portfolio Analysis 11.16.4. Business Strategy & Recent Development 11.17. Xtant Medical 11.17.1. Company overview 11.17.2. Financial performance 11.17.3. Product Portfolio Analysis 11.17.4. Business Strategy & Recent Development List of Tables (67 Tables) TABLE 1. Market, By Product, 2021-2030 (USD Million) TABLE 2. Market FOR Cartilage, BY REGION, 2021-2030 (USD Million) TABLE 3. Market FOR Tendon Allograft, BY REGION, 2021-2030 (USD Million) TABLE 4. Market FOR Meniscus Allograft, BY REGION, 2021-2030 (USD Million) TABLE 5. Market FOR Dental Allograft, BY REGION, 2021-2030 (USD Million) TABLE 6. Market FOR Collagen Allograft, BY REGION, 2021-2030 (USD Million) TABLE 7. Market FOR Amniotic Allograft, BY REGION, 2021-2030 (USD Million) TABLE 8. Market, By End-User, 2021-2030 (USD Million) TABLE 9. Market FOR Hospitals, BY REGION, 2021-2030 (USD Million) TABLE 10. Market FOR Orthopedic Clinics, BY REGION, 2021-2030 (USD Million) TABLE 11. Market FOR Dental Clinics, BY REGION, 2021-2030 (USD Million) TABLE 12. Market FOR Ambulatory Service Centers, BY REGION, 2021-2030 (USD Million) TABLE 13. Market FOR Aesthetic Centers, BY REGION, 2021-2030 (USD Million) TABLE 14. Market, BY APPLICATION, 2021-2030 (USD Million) TABLE 15. Market FOR Orthopedic, BY REGION, 2021-2030 (USD Million) TABLE 16. Market FOR Dentistry, BY REGION, 2021-2030 (USD Million) TABLE 17. Market FOR Wounded care, BY REGION, 2021-2030 (USD Million) TABLE 18. Market FOR Others, BY REGION, 2021-2030 (USD Million) TABLE 19. Market, BY REGION, 2021-2030 (USD Million) TABLE 20. NORTH AMERICA Market, BY COUNTRY, 2021-2030 (USD Million) TABLE 21. NORTH AMERICA Market, By Product, 2021-2030 (USD Million) TABLE 22. NORTH AMERICA Market, By End-User, 2021-2030 (USD Million) TABLE 23. NORTH AMERICA Market, BY APPLICATION, 2021-2030 (USD Million) TABLE 24. EUROPE Market, BY COUNTRY, 2021-2030 (USD Million) TABLE 25. EUROPE Market, By Product, 2021-2030 (USD Million) TABLE 26. EUROPE Market, By End-User, 2021-2030 (USD Million) TABLE 27. EUROPE Market, BY APPLICATION, 2021-2030 (USD Million) TABLE 28. ASIA-PACIFIC Market, BY COUNTRY, 2021-2030 (USD Million) TABLE 29. ASIA-PACIFIC Market, By Product, 2021-2030 (USD Million) TABLE 30. ASIA-PACIFIC Market, By End-User, 2021-2030 (USD Million) TABLE 31. ASIA-PACIFIC Market, BY APPLICATION, 2021-2030 (USD Million) TABLE 32. LAMEA Market, BY COUNTRY, 2021-2030 (USD Million) TABLE 33. LAMEA Market, By Product, 2021-2030 (USD Million) TABLE 34. LAMEA Market, By End-User, 2021-2030 (USD Million) TABLE 35. LAMEA Market, BY APPLICATION, 2021-2030 (USD Million) TABLE 36. MiMedix Group.: COMPANY SNAPSHOT TABLE 37. MiMedix Group.: OPERATING SEGMENTS TABLE 38. Zimmer Biomet: COMPANY SNAPSHOT TABLE 39. Zimmer Biomet: OPERATING SEGMENTS TABLE 40. Lattice Biologics Ltd: COMPANY SNAPSHOT TABLE 41. Lattice Biologics Ltd: OPERATING SEGMENTS TABLE 42. Alon Source: COMPANY SNAPSHOT TABLE 43. Alon Source: OPERATING SEGMENTS TABLE 44. Conmed Coporation: COMPANY SNAPSHOT TABLE 45. Conmed Coporation: OPERATING SEGMENTS TABLE 46. AlloSource: COMPANY SNAPSHOT TABLE 47. AlloSource: OPERATING SEGMENTS TABLE 48. Osiris Therapeutics: COMPANY SNAPSHOT TABLE 49. Osiris Therapeutics: OPERATING SEGMENTS TABLE 50. Globus Medical, Inc: COMPANY SNAPSHOT TABLE 51. Globus Medical, Inc: OPERATING SEGMENTS TABLE 52. Organogenesis, Inc.: COMPANY SNAPSHOT TABLE 53. Organogenesis, Inc.: OPERATING SEGMENTS TABLE 54. Integra Life Sciences Corporation: COMPANY SNAPSHOT TABLE 55. Integra Life Sciences Corporation: OPERATING SEGMENTS TABLE 56. RTI Surgical, Inc: COMPANY SNAPSHOT TABLE 57. RTI Surgical, Inc: OPERATING SEGMENTS TABLE 58. Straumann Holding AG: COMPANY SNAPSHOT TABLE 59. Straumann Holding AG: OPERATING SEGMENTS TABLE 60. Arthrex: COMPANY SNAPSHOT TABLE 61. Arthrex: OPERATING SEGMENTS TABLE 62. Alliqua BioMedical, Inc: COMPANY SNAPSHOT TABLE 63. Alliqua BioMedical, Inc: OPERATING SEGMENTS TABLE 64. Bard, Inc. (Davol, Inc.) Braun Melsungen AG: COMPANY SNAPSHOT TABLE 65. Bard, Inc. (Davol, Inc.) Braun Melsungen AG: OPERATING SEGMENTS TABLE 66. Xtant Medical: COMPANY SNAPSHOT TABLE 67. Xtant Medical: OPERATING SEGMENTS List of Figures (22 Figures) Figure 1 Soft Tissue Allografts Market: Research Methodology Steps Figure 2 Research Design Figure 3 Breakdown of Primaries: Market Figure 4 Research Methodology: Hypothesis Building Figure 5 Market: Product-Based Estimation Figure 6 Top 16 Companies with Highest No. Of Patent in Last 9 Years Figure 7 No. Of Patents Granted Per Year, 2019–2020 Figure 8 Import Data for Soft Tissue Allografts, By Country, 2016–2020 (USD Thousand) Figure 9 Export Data for Soft Tissue Allografts, By Country, 2016–2020 (USD Thousand) Figure 10 Data Triangulation Methodology Figure 11 Market, By End-User, 2019 vs 2025 (USD Million) Figure 12 Market Share, By Application, 2019 vs 2025 (USD Million) Figure 13 Market Share, By Product, 2019 vs 2025 (USD Million) Figure 14 Geographical Snapshot of the Market Figure 15 Collagen Allograft to Witness Higher CAGR in Market for Product Segment during Forecast Period. Figure 16 Orthopedic to Witness Higher CAGR in Market for Application Segment during Forecast Period. Figure 17 Hospitals to Witness Higher CAGR in the Market for End-User Segment during Forecast Period. Figure 18 North America Region Accounted for the Largest Share of the Market, By Regional Basis, in 2019 Figure 19 Market: Drivers, Restraints, Opportunities, and Challenges Figure 20 North America: Market Snapshot Figure 21 Asia Pacific: Market Snapshot Figure 22 Vendor Dive: Evaluation Overview